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A Crossover Intervention Trial Evaluating the Efficacy
of a Chlorhexidine-Impregnated Sponge in Reducing
Catheter-Related Bloodstream Infections
among Patients Undergoing Hemodialysis
Bernard C. Camins, MD, MSCR; Amy M. Richmond, RN, MHS, CIC; Kathrin L. Dyer, MPH;
Heather N. Zimmerman, MPH; Daniel W. Coyne, MD; Marcos Rothstein, MD; Victoria J. Fraser, MD
background. Catheter-related bloodstream infections (CRBSIs) account for the majority of hemodialysis-related infections. There are
no published data on the efficacy of the chlorhexidine-impregnated foam dressing at reducing the rate of CRBSI among patients undergoing
hemodialysis.
design. A prospective, nonblinded, crossover intervention trial to determine the efficacy of a chlorhexidine-impregnated foam dressing
to reduce the rate of CRBSI among patients undergoing hemodialysis.
setting. Two outpatient dialysis centers.
patients. A total of 121 patients who underwent dialysis through tunneled central venous catheters received the intervention during
the trial.
methods. The primary outcome of interest was the incidence of CRBSI. A nested cohort study of all patients who received the
chlorhexidine-impregnated foam dressing was also conducted. Backward stepwise logistic regression analysis was used to determine in-
dependent risk factors for development of CRBSI.
results. Thirty-seven CRBSIs occurred in the intervention group, for an incidence of 6.3 CRBSIs per 1,000 dialysis sessions, and 30
CRBSIs occurred in the control group, an incidence of 5.2 CRBSIs per 1,000 dialysis sessions (risk ratio, 1.22 [95% confidence interval
{CI}, 0.75–1.97]; Pp .46). The chlorhexidine-impregnated foam dressing was well tolerated, with only 2 patients (!2%) experiencing
dermatitis that led to its discontinuation. The only independent risk factor for development of CRBSI was dialysis treatment at one dialysis
center (adjusted odds ratio, 4.4 [95% CI, 1.77–13.65]; Pp .002). Age of at least 60 years (adjusted odds ratio, 0.28 [95% CI, 0.09–0.82];
Pp .02) was associated with lower risk of CRBSI.
conclusions. The use of a chlorhexidine-impregnated foam dressing did not decrease the incidence of CRBSI among patients with
tunneled central venous catheters who were undergoing hemodialysis.
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Infections account for 16%–36% of all deaths among adults
with end-stage renal disease.1,2 The risk of bloodstream in-
fection (BSI) among patients undergoing hemodialysis is sig-
nificantly higher for those undergoing hemodialysis through
a central venous catheter than for those undergoing hemo-
dialysis through arteriovenous (AV) fistulae or grafts.3-5 Maki
et al6 reported that a silver-impregnated cuff placed on the
catheter hub decreased the rate of nontunneled catheter–re-
lated bacteremia almost 4-fold. Routine application of pov-
idone-iodine ointment to temporary hemodialysis catheters
was also shown to be effective in reducing catheter-related
infections.7
The Biopatch Antimicrobial Dressing (Johnson & Johnson
Wound Management, a division of Ethicon) is a novel cath-
eter dressing impregnated with chlorhexidine gluconate. It is
used in conjunction with the standard catheter dressing to
prevent catheter-related BSI (CRBSI). The chlorhexidine-im-
pregnated dressing was shown to be effective in reducing
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microbial colonization of epidural catheters.8 A randomized
clinical trial performed with neonates who had central venous
catheters in place demonstrated that the chlorhexidine-im-
pregnated foam dressing, compared with the povidone-iodine
rub, significantly decreased the rate of colonization of the
central venous catheter but not the incidence of CRBSI.9
Among neutropenic patients, a randomized, controlled trial
showed that use of a chlorhexidine-impregnated dressing with
tunneled central venous catheters resulted in fewer docu-
mented exit-site infections, but there was no difference in the
catheter removal rate between the intervention and control
groups.10 Timsit et al11 recently published a randomized, con-
trolled trial demonstrating the efficacy of the chlorhexidine-
impregnated foam dressing at reducing the rate of CRBSI
among critically ill patients with nontunneled central venous
catheters.
To our knowledge, there are currently no published studies
of the efficacy of the chlorhexidine-impregnated foam dress-
ing in patients undergoing hemodialysis. We recently con-
ducted a crossover intervention trial to study the efficacy of
the chlorhexidine-impregnated foam dressing to reduce the
incidence of CRBSI among patients undergoing hemodialysis
in an outpatient setting.
methods
We conducted a prospective, crossover intervention trial at
2 outpatient hemodialysis centers affiliated with Washington
University School of Medicine and Barnes-Jewish Hospital in
Saint Louis, Missouri, during the period from April 1, 2005,
through March 31, 2006. Informed consent was obtained
from patients before administration of the chlorhexidine-im-
pregnated foam dressing. Any patient who underwent he-
modialysis through a tunneled central venous catheter re-
ceived the intervention if the dialysis center where he or she
underwent dialysis were in the intervention arm of the study.
The intervention was continued for every patient who un-
derwent dialysis through a central venous catheter until the
intervention period was over, the patient transferred his or
her care to a different facility, until a central venous catheter
was no longer necessary (ie, an AV graft or fistula was in
place), or if the patient was intolerant of the intervention.
The only exclusion criterion was a reported allergy to chlor-
hexidine-gluconate. This study was approved by the Wash-
ington University Human Research Protection Office.
Sample Size Estimate
In the 6-month period before the study, the combined in-
cidence of CRBSI at both dialysis centers was 7.05 CRBSIs
per 1,000 dialysis sessions, or 40 distinct CRBSIs after 5,766
dialysis sessions. On the basis of the study by Maki et al,6 use
of the chlorhexidine-impregnated foam dressing decreased
the CRBSI rate by 62% (unpublished data). This suggested
that if this intervention worked on dialysis catheters, the
number of CRBSIs in the intervention group should decrease
to 16 distinct CRBSIs in 5,766 dialysis sessions (2.28 CRBSIs
per 1,000 dialysis sessions). On the basis of the number of
dialysis sessions that occurred in the baseline period at both
dialysis centers, we would have accumulated an adequate
number of dialysis sessions within 1 year. This difference
would have been statistically significant, with a P value of less
than .001.
Protocols for routine catheter care before the study in-
cluded the use of a sodium hypochlorite solution (0.114%
by volume) for skin and/or catheter antisepsis prior to each
dialysis session. The catheter exit site was dressed with a
transparent dressing every 7 days unless there was visible
blood or soiling or if the dressing came off. The same dressing
change schedule was continued when the intervention began.
A new dialysis catheter care protocol incorporating the use
of the chlorhexidine-impregnated foam dressing was insti-
tuted and standardized at both hemodialysis centers at the
start of the intervention. The only difference between the
catheter care protocols of the hemodialysis centers during the
study was the use of the chlorhexidine-impregnated foam
dressing. Both dialysis centers had the same nurse-to-patient
ratio and shared the same infection-prevention specialist, and
although each had its own medical director, both were in the
renal division of the affiliated medical school. The interven-
tion was initiated in dialysis center A during the first 6-month
period, whereas dialysis center B patients served as the control
group. After 6 months, the chlorhexidine-impregnated foam
dressing use was discontinued at dialysis center A and its use
was instituted in dialysis center B. A nested cohort study
including only patients for whom the chlorhexidine-impreg-
nated foam dressing (intervention group) was applied was
also performed to determine risk factors for development of
CRBSI in this select population. CRBSIs were monitored by
the infection control practitioner and the dialysis center staff.
All blood cultures for all hemodialysis patients at the 2 dialysis
centers were reviewed, as well were all of their hospital ad-
missions, to identify CRBSI. Demographic information and
all clinical data were collected from the Cyberren Database
(Cybernius Medical), a clinical data management system for
nephrology used by both dialysis centers.
Definitions
Definitions for infections were based on the Centers for Dis-
ease Control and Prevention National Nosocomial Infections
Surveillance System guidelines,12 with some modifications. A
CRBSI was defined as a positive blood culture at the time
the catheter was in place or within 48 hours after catheter
removal, along with clinical signs and symptoms of sepsis
(fever [temperature greater than 38.0C] or hypotension [sys-
tolic blood pressure less than 90 mm Hg]) and no other
documented primary site of infection. An infection was con-
sidered new only if the patient had not received any treatment
for a catheter-related infection in the 21 days before the cur-
rent infection. Assessment of the primary outcome was per-
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(n p 66) P
Sex
Male 52 (43) 25 (45) 27 (41) .75
Female 69 (57) 31 (55) 39 (59)
Age, years, median (range) 56 (19–88) 57 (26–87) 56 (19–88) .93
Race
African American 97 (80) 42 (76) 55 (83) .46
White 23 (19) 13 (24) 10 (15)
Other 1 (1) 0 (0) 1 (2)
BMI, median (range) 27.1 (14.7–71.6) 25.9 (16.3–53.6) 27.8 (14.8–71.6) .31
note. Data are no. (%) of patients, unless otherwise indicated. BMI, body mass index (calculated as weight
in kilograms divided by the square of height in meters).
figure 1. Results of the crossover intervention trial. CRBSI,
catheter-related bloodstream infection.
formed by the infection prevention specialist (A.M.R.), and
adverse events were assessed by the principal investigator
(B.C.C.). Both investigators were not blinded to the period
in which the outcome occurred.
Outcomes
The primary outcome for this study was the incidence of
CRBSI in the 2 groups measured in the number of CRBSIs
per 1,000 dialysis sessions. A secondary outcome studied was
the tolerability of prolonged used of the chlorhexidine-im-
pregnated foam dressing. Infection rates between the control
and intervention groups were compared using x2 analysis.
For the nested cohort study, a patient who developed a CRBSI
was only counted as a case patient once, even if he or she
had multiple episodes of CRBSI, for the purposes of deter-
mining risk factors. Thirty-one patients accounted for 67 dis-
tinct episodes of CRBSI over the study period. Bivariate anal-
ysis of categorical variables in the cohort study was performed
using the Mantel Hansel x2 test or the Fisher exact test. Con-
tinuous variables were compared using the Student t test or
the Mann-Whitney U test. A 2-sided P value of less than or
equal to .05 was considered to denote statistical significance.
Multivariate analysis using backward stepwise logistic re-
gression was performed to determine independent risk factors
for development of a CRBSI. The final model was determined
using the Hosmer-Lemeshow goodness-of-fit test. Interac-
tions between variables were also tested, but no statistically
significant interactions were demonstrated. Variables that
were found to have a P value of less than or equal to .1 on
bivariate analysis were included in the multivariate analysis
logistic regression model. Data analysis was performed using
SPSS, version 14 (SPSS).
results
One hundred twenty-one patients with tunneled central ve-
nous catheters were treated with the chlorhexidine-impreg-
nated dressing at both dialysis centers over the 1-year period.
Two patients withdrew consent after just 2 dialysis sessions,
so use of the chlorhexidine-impregnated foam dressing was
discontinued for these patients. Baseline patient character-
istics are listed in Table 1. The intent-to-treat analysis in-
cluded 5,847 dialysis sessions in the intervention period and
5,764 dialysis sessions in the control period. There were
37 CRBSIs during the intervention period (incidence, 6.3
CRBSIs per 1,000 dialysis sessions) and 30 CRBSIs during
the control period (incidence, 5.2 CRBSIs per 1,000 dialysis
sessions; relative risk [RR], 1.22 [95% confidence interval
{CI}, 0.75–1.97]; Pp .46) (Figure 1). In 2 patients (less than
2%), the use of the chlorhexidine-impregnated foam dressing
was discontinued because of adverse events. Both patients
were thought to have developed dermatitis, but 1 patient
concomitantly received antimicrobial therapy for an exit-site
infection, because it was difficult to ascertain whether the
erythema was due to contact dermatitis or infection.
Variables studied for development of CRBSI on bivariate
analysis are shown in Table 2. Receipt of hemodialysis at
dialysis center A, a history of substance abuse, and frequent
efficacy of a chlorhexidine-impregnated dressing 1121







(n p 90) P
Sex
Male 17 (55) 35 (39) .12
Female 14 (45) 55 (61)
Race
African American 24 (77) 73 (81) .72
White 7 (23) 16 (18)
Age, x60 years 7 (23) 41 (47) .02
Age, median years 53 57 .01
Dialysis center
A 22 (71) 33 (37) .001
B 9 (9) 57 (63)
Hypertension 31 (100) 83 (97) .29
Congestive heart failure 2 (7) 20 (23) .04a
Diabetes 18 (58) 41 (48) .32
Obesity 11 (36) 17 (20) .08
Peripheral vascular disease 9 (29) 19 (22) .44
Receipt of immunosuppressants 1 (3) 5 (6) .39
COPD and/or asthma 5 (16) 9 (11) .41
Hepatitis B or C 3 (10) 5 (6) .47
Cerebrovascular accident history 7 (23) 15 (17) .53
HIV infection 1 (3) 1 (1) .45
Tobacco use 3 (10) 17 (20) .20
Substance abuse 5 (16) 1 (1) .005a
History of surgery in past 30 days 3 (10) 14 (16) .37
Admission in past 30 days 5 (16) 29 (34) .06
Previous CRBSI in past 90 days 4 (13) 9 (11) .71
Receipt of antibiotics in the past 30 days 3 (10) 18 (21) .19
Dressing changes
Once per week 11 (33) 53 (62) .01
More than once per week 20 (67) 33 (38)
note. Data are no. (%) of patients, unless otherwise indicated. COPD, chronic obstructive pulmonary
disease.
a Determined by the Fisher exact test.
table 3. Independent Risk Factors for Development
of Catheter-Related Bloodstream Infection
Variable aOR (95% CI) P
Care at dialysis center A 4.9 (1.77–13.7) .002
Obesity 2.4 (0.89–6.63) .08
Age, x60 years 0.28 (0.09–0.82) .02
note. aOR, adjusted odds ratio; CI, confidence interval.
dressing changes (more than once per week) were significant
risk factors for development of CRBSI on bivariate analysis.
A history of congestive heart failure and age of at least 60
years were associated with decreased risk of developing a
CRBSI. Two variables on bivariate analysis had P values of
less than .1: obesity (increased risk) and admission to the
hospital in the previous 30 days (decreased risk). Demo-
graphic variables, such as age, sex, and race, as well as obesity,
hospital admission in the past 30 days, frequency of dressing
changes, and dialysis center, were included in the multivariate
analysis model. The only independent predictor for devel-
opment of CRBSI was dialysis treatment at dialysis center A.
Age of at least 60 years was associated with decreased risk of
developing a CRBSI (Table 3).
discussion
This is the first intervention trial using a chlorhexidine-im-
pregnated foam dressing to reduce the risk of CRBSI in out-
patient hemodialysis patients. Other investigators have stud-
ied other methods of reducing CRBSI among patients
undergoing hemodialysis. Lok et al13 randomized 169 patients
receiving hemodialysis through a central venous catheter to
receive either polysporin triple antibiotic ointment or placebo
over a 6-month period. Fewer infections were observed in
the treatment group (12% vs 34%; Pp .001). The incidence
of bacteremia was also lower in the treatment group. (0.63
vs 2.48 cases of bacteremia per 1,000 catheter-days; Pp .0004).
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Johnson et al14 also enrolled 50 patients in an open-label,
randomized trial comparing the application of mupirocin
(np 27) thrice weekly around tunneled cuffed hemodialysis
catheter exit sites versus the standard of care. Mupirocin-
treated patients experienced significantly fewer catheter-re-
lated cases of bacteremia (7% vs 35%; P ! .01). The mupi-
rocin intervention also resulted in a delay in the occurrence
of bacteremia (108 vs 55 days; P ! .01). The same group of
investigators conducted a similar study, but this time they
randomly assigned patients to receive either thrice-weekly
applications of honey or mupirocin at the catheter exit site,
to reduce the risk of CRBSI. A total of 101 patients were
enrolled in this open-label trial (51 honey-treated patients
and 50 mupirocin-treated patients). The 2 interventions pro-
duced similar rates of CRBSI. Although the authors did not
report an increase in mupirocin resistance, they did conclude
that the use of honey is associated with a lower risk of de-
velopment of resistance.15
Aside from the application of honey around the exit-site
to prevent CRBSI, all of the interventions above have the
potential for the development of antimicrobial resistance that
may render the intervention ineffective. The use of a chlor-
hexidine-impregnated foam dressing to prevent CRBSI would
have a decreased potential for the development of resistance,
but in our study this intervention did not decrease the in-
cidence of CRBSI among hemodialysis patients with tunneled
central venous catheters. We speculate that the catheter exit
site may have a reduced role in the pathogenesis of CRBSI
in tunneled central venous catheters. The catheter hub may
play a larger role in the pathogenesis of CRBSI in this patient
population. The risk of CRBSI due to catheter hub bacterial
colonization would not be affected by application of the
chlorhexidine-impregnated foam dressing.
A unique aspect of this study is the cohort study that
provides new information on potentially modifiable risk fac-
tors for the development of CRBSI among patients under-
going hemodialysis through central venous catheters. Previ-
ous studies have shown that the optimal vehicle for hemo-
dialysis is an AV fistula or graft, because those pose less risk
for CRBSI.16,17 Central venous catheters in this cohort were
used only as a temporizing vascular access until an AV fistula
or graft was available or as last resorts. Most of the studies
on risk factors for bacteremia among hemodialysis patients
were based on large data sets containing only codes from The
International Classification of Diseases, Ninth Revision. Risk
factors for CRBSI reported in the literature include older age,
female sex, and African American race.18,19 Potentially mod-
ifiable risk factors include hemodialysis versus peritoneal di-
alysis, temporary catheter versus permanent catheter use, low
serum albumin level, and dialyzer reuse. Although diabetes
mellitus can be controlled through insulin therapy and diet,
it is unknown whether strict control of blood glucose levels
leads to a decreased risk of CRBSI among patients undergoing
hemodialysis. Data on the contribution of diabetes to the
development of CRBSI have been conflicting.17-19 In this study,
we discovered that one dialysis center had a higher risk for
CRBSI. The potential differences between the 2 centers in-
clude more frequent dressing changes (54% vs 39%; Pp .1)
and more patients with a history of substance abuse (9% vs
2%; Pp .1) received hemodialysis at dialysis center A. More
frequent dressing changes were found to be associated with
CRBSI on bivariate analysis, but this factor was eliminated
from the logistic regression model because treatment at di-
alysis center A was a stronger predictor for CRBSI. Frequent
dressing changes may lead to higher risk for contamination.
On the other hand, they may also be a surrogate marker for
frequent bleeding, more perspiration, or poor personal hy-
giene. A history of substance abuse was also a risk factor for
CRBSI on bivariate analysis. Additional investigation is re-
quired to determine whether this association is due to relative
immunosuppression related to substance abuse, catheter ma-
nipulation, personal hygiene differences, staphylococci col-
onization differences, and other factors.
Age of at least 60 years was associated with decreased risk
of CRBSI, a finding inconsistent from those of previous
studies.18,19 The real reason for this finding is unknown; how-
ever, obesity and frequent dressing changes in this cohort
(both had P values of less than .1 as risk factors on bivariate
analysis) were associated with younger age (mean age, 51.2
vs 67.4 years; Pp .01). The underlying reason that older age
(ie, at least 60 years) was associated with decreased risk of
CRBSI may have been that these patients were less likely to
be obese and were more likely to adhere to the weekly dressing
changes. The small sample size may have contributed to these
individual risk factors (obesity and frequent dressing changes)
not being independent risk factors for development of CRBSI
in the logistic regression model.
This study has a few limitations. This study was not a
randomized controlled trial. Randomization would have al-
lowed for stratification on the type of catheter and dialysis
center to remove potential biases. However this would have
required a much bigger study population and inclusion of
multiple dialysis centers, which would have been very costly.
Despite careful standardization of the catheter care protocol
and other processes of care, there were still differences in the
dialysis center populations that may have affected the results
of the study. These differences can be effectively accounted
for by a randomized, controlled trial. The power analysis was
based on previous efficacy data, which showed a 62% decrease
in CRBSI rates among patients with nontunneled central ve-
nous catheters. Our study may not have had sufficient power
to show a small difference in CRBSI rates between the in-
tervention and control groups. Finally, there was no “wash-
out” period before the crossover took place. It is unlikely that
this would have had an impact on the results of the study,
because the first CRBSI after crossover occurred more than
3 weeks after the date of the crossover.
Although not essential to evaluate the primary outcomes
of this study, microbiological cultures of the catheter hubs or
catheter exit sites were not done, so we were not able to
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compare these with the bacterial isolates obtained from blood
cultures collected from the patients in the trial. Information
on organisms colonizing the skin and the catheter hubs could
have helped elucidate the mechanisms behind the develop-
ment of CRBSI in these hemodialysis patients. Nevertheless,
this is the second largest intervention trial involving the exit
site on patients who underwent dialysis through tunnelled
central venous catheters to date. The crossover intervention
trial design also has increased validity over a before-and-after
intervention trial.
In a crossover intervention trial, the chlorhexidine-im-
pregnated foam dressing did not significantly decrease CRBSI
among patients undergoing hemodialysis with tunneled cen-
tral venous catheters. In previous studies, application of an-
tibiotics, such as mupirocin or polysporin, has been shown
to be an effective intervention, so such interventions should
be considered first to reduce the incidence of CRBSI among
patients undergoing hemodialysis. The development of re-
sistance to these antibiotics may still limit their use over long
periods of time. Older age (at least 60 years) was associated
with decreased risk of CRBSI in our patient population.
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